ANEMIA & BLOOD
This is the medical term for a decrease in red blood cells, hemoglobin, or hematocrit, resulting in reduced oxygen-carrying capacity of the blood.
What is anemia?
HIV stands for this virus that attacks CD4 T-helper cells, progressively weakening the immune system.
What is Human Immunodeficiency Virus?
What is Human Immunodeficiency Virus?
This type of infection control precaution is used for ALL patients and includes hand hygiene, gloves, and proper disposal of sharps.
What are Standard Precautions?
Cyanocobalamin (Nascobal) is the synthetic form of this vitamin used to treat pernicious anemia and is often given via intramuscular injection.
What is Vitamin B12 (or cobalamin)?
Before administering any blood product, the nurse must verify the patient’s identity and blood product compatibility using this two-person verification process.
What is dual verification (or two-person ID check)?
Details: - Two licensed nurses (or nurse + provider) -Verify TOGETHER at bedside: - Patient name, DOB, MRN (check armband) - Blood product label (patient name, DOB, blood type) - Compatibility (ABO, Rh match) - Expiration date - Blood unit number - Both sign transfusion record - Critical safety step: Prevents wrong blood transfusion (can be fatal)
What is tachycardia (or palpitations, increased heart rate)? Additional anemia symptoms: - Dyspnea on exertion - Weakness, dizziness - Cold intolerance - Headache - Pale conjunctiva, nail beds, mucous membranes
The classic triad of anemia symptoms includes fatigue, pallor, and this symptom caused by the heart compensating for decreased oxygen delivery.
This lab value measures immune function in HIV patients. When it drops below 200 cells/mm³, the patient is diagnosed with AIDS (Acquired Immunodeficiency Syndrome).
What is CD4 count (or CD4 T-cell count)?
Additional: - Normal CD4: 500-1,500 cells/mm³ - AIDS diagnosis: CD4 <200 OR opportunistic infection -Treatment goal: Viral suppression, CD4 increase
MRSA (Methicillin-Resistant Staphylococcus aureus) requires this type of transmission-based precaution, which includes gown and gloves for all patient contact.
What are Contact Precautions? Additional: - Contact precautions also for: C. difficile, VRE, scabies, multidrug-resistant organisms - Private room or cohort patients with same organism - Dedicated equipment when possible
This broad-spectrum penicillin antibiotic is often the first-line treatment for common bacterial infections like strep throat, ear infections, and urinary tract infections.
What is amoxicillin (Amoxil)?
For the first 15 minutes of a blood transfusion, the nurse must remain with the patient or check frequently because most serious transfusion reactions occur during this time period.
What are the first 15 minutes (or initial phase)? Transfusion protocol: - Start slowly: 50 mL/hour × 15 minutes (or per protocol) - Stay at bedside or check Q 5 minutes - Most severe reactions (acute hemolytic, anaphylactic) occur early - After 15 minutes: If no reaction, can increase rate (typically to 200-250 mL/hour)
What is megaloblastic anemia (or macrocytic anemia)? Key points: - Pernicious anemia: Specific type caused by lack of intrinsic factor (can’t absorb B12) - B12 sources:Animal products (meat, dairy, eggs) - Folate sources: Leafy greens, citrus, beans - Neurological symptoms: B12 deficiency causes peripheral neuropathy (numbness/tingling), balance problems, confusion
This type of anemia is caused by vitamin B12 or folate deficiency and results in abnormally large, immature red blood cells that cannot carry oxygen effectively.
The goal of antiretroviral therapy (ART) for HIV is to suppress this lab value to undetectable levels (<50 copies/mL), which prevents disease progression and transmission.
What is viral load (or HIV RNA)?
Key teaching: - U=U: Undetectable = Untransmittable - If viral load is undetectable for 6+ months → cannot transmit HIV sexually - Adherence to ART is critical (>95% of doses)
Tuberculosis requires Airborne Precautions with a negative pressure room and this specific type of respirator that filters particles ≥0.3 microns.
What is an N95 respirator (or PAPR—powered air-purifying respirator)? Key points: - Fit testing required annually for N95 - Do NOT use surgical masks for airborne precautions (insufficient) - Patient wears surgical mask if must leave room
When prescribing antibiotics, this laboratory test identifies the specific bacteria causing infection and determines which antibiotics will be effective against it.
What is culture and sensitivity (C&S)? Additional: - Culture: Identifies organism - Sensitivity:Tests antibiotic susceptibility (reports as S, I, R) - S (Sensitive): Drug should work - I (Intermediate): May work at higher doses - R (Resistant): Drug will not work -Takes 24-72 hours for final results
This life-threatening transfusion reaction occurs when ABO-incompatible blood is given, causing rapid hemolysis, back pain, fever, hypotension, and dark urine. It is usually caused by clerical error.
What is an acute hemolytic transfusion reaction (AHTR)?
Key points: - Antibodies in recipient attack donor RBCs- Most common cause: ABO incompatibility (wrong blood given) - Symptoms: - Fever, chills (first sign) - Back/flank pain (kidney area—hemoglobin damaging kidneys) - Chest pain, dyspnea - Hypotension, tachycardia (shock) - Dark urine (hemoglobinuria—RBC breakdown products) - Bleeding (DIC can develop) - EMERGENCY: - STOP transfusion immediately - Keep IV open with NS (new tubing) - Notify provider STAT - Monitor urine output (maintain >100 mL/hr—prevent kidney damage) - Send blood bag + tubing to lab, obtain post-transfusion samples
PATHOPHYSIOLOGY COMPARISON: Compare and contrast these THREE types of anemia. For EACH, include: cause, RBC characteristics, and ONE key lab finding. Iron deficiency anemia Pernicious anemia (B12 deficiency) Sickle cell anemia
Iron deficiency anemia: chronic blood loss, low dietary iron, or malabsorption; microcytic hypochromic RBCs; low ferritin, low serum iron, high TIBC, low MCV.
Pernicious anemia: lack of intrinsic factor causing B12 malabsorption; macrocytic/megaloblastic RBCs with hypersegmented neutrophils; low B12, high MCV, positive anti-intrinsic factor antibodies.
Sickle cell anemia: inherited HbS mutation; crescent-shaped rigid RBCs with hemolysis; hemoglobin electrophoresis shows HbS, with elevated reticulocytes/bilirubin.
HIV MEDICATION CLASSES: Match each antiretroviral drug class to its mechanism of action:
Drug Classes: 1. NRTIs (Nucleoside Reverse Transcriptase Inhibitors) – zidovudine (Retrovir) 2. NNRTIs (Non-Nucleoside Reverse Transcriptase Inhibitors) – delavirdine3. Protease Inhibitors – ritonavir (Norvir) 4. Integrase Inhibitors – raltegravir (Isentress) 5. Entry/Fusion Inhibitors – enfuvirtide (Fuzeon) 6. CCR5 Antagonists – maraviroc (Selzentry)
Mechanisms: - A) Prevents HIV from entering CD4 cells by blocking CCR5 co-receptor - B) Blocks HIV protease enzyme, preventing maturation of viral particles - C) Prevents integration of viral DNA into host cell DNA - D) Blocks reverse transcriptase by incorporating fake nucleosides - E) Binds directly to reverse transcriptase enzyme, changing its shape - F) Prevents HIV from fusing with and entering CD4 cells
Drug Class
Mechanism
Matching Letter
NRTIs (zidovudine)
D) Blocks reverse transcriptase by incorporating fake nucleosides into viral DNA, causing chain termination
Acts as “fake building blocks”that stop viral DNA copying
NNRTIs (delavirdine)
E) Binds directly to reverse transcriptase enzyme, changing its shape so it can’t function
Non-competitive inhibition (doesn’t mimic nucleosides)
Protease Inhibitors(ritonavir)
B) Blocks HIV protease enzyme, preventing cleavage of viral polyproteins into functional proteins
Viral particles produced are immature and non-infectious
Integrase Inhibitors(raltegravir)
C) Prevents integration of viral DNA into host cell DNA
Blocks the integrase enzyme from “cutting and pasting” viral DNA into human DNA
Entry/Fusion Inhibitors (enfuvirtide)
F) Prevents HIV from fusing with and entering CD4 cells
Blocks gp41 protein that HIV uses to fuse with cell membrane;given as subcutaneous injection
CCR5 Antagonists(maraviroc)
A) Prevents HIV from entering CD4 cells by blocking CCR5 co-receptor
Binds to CCR5 receptor on CD4 cells, preventing HIV attachment; only works for CCR5-tropic HIV
CRITICAL TEACHING:
Why Combination Therapy (ART) is Essential: - Prevent resistance: Using 3+ drugs from ≥2 classes - If one drug stops working (resistance mutation), others still effective -Suppress viral replication at multiple steps
Common ART Regimens: - “Backbone”: 2 NRTIs (e.g., tenofovir + emtricitabine) - “Third agent”: NNRTI, integrase inhibitor, or protease inhibitor - Single-tablet regimens available: Improve adherence (Biktarvy, Triumeq, Genvoya)
Nursing Implications: - Adherence is CRITICAL:Missing doses → resistance - Take at same time daily -Many drug interactions: Check ALL medications - Side effects vary by class: - NRTIs: Lactic acidosis (rare), lipodystrophy - NNRTIs: Rash (can be severe—Stevens-Johnson syndrome) - PIs: GI upset, lipid abnormalities, insulin resistance - Integrase inhibitors: Generally well-tolerated (fewest side effects)
ANTIBIOTIC RESISTANCE SCENARIO: Your hospital’s antibiogram shows: - E. coli: 45% resistant to ampicillin, 20% resistant to ciprofloxacin - MRSA: 65% of S. aureus isolates are methicillin-resistant - VRE:Increasing vancomycin-resistant Enterococcus cases Answer: 1. What is an antibiogram and why is it important?2. Explain THREE mechanisms of antibiotic resistance. 3. What are FOUR nursing actions to prevent antimicrobial resistance? 4. A patient has MRSA pneumonia. Which antibiotics would you anticipate? (Name 2 and explain why)
An antibiogram is a local report of bacterial susceptibility/resistance patterns that guides empiric antibiotics and tracks resistance trends. Resistance mechanisms include enzymatic destruction such as beta-lactamases, altered target sites such as MRSA PBP2a or VRE D-Ala-D-Lac, and efflux pumps that remove the drug. Nursing actions: hand hygiene and asepsis, obtain cultures before antibiotics, support de-escalation/antibiotic timeouts, and use correct isolation/environmental cleaning. MRSA pneumonia: anticipate vancomycin or linezolid; do not use daptomycin for pneumonia.
ANTIBIOTIC CLASSES CHALLENGE:
Match each antibiotic to its class and ONE major nursing consideration:
Antibiotics: 1. Amoxicillin/clavulanate (Augmentin) 2. Cephalexin (Keflex) 3. Vancomycin (Vancocin) 4. Gentamicin 5. Metronidazole (Flagyl) 6. Rifampin (Rifadin)
Drug Classes: - Beta-lactam combination (penicillin + beta-lactamase inhibitor) - Cephalosporin (1st generation) - Glycopeptide - Aminoglycoside - Nitroimidazole (antiparasitic/antibacterial) - Antimycobacterial
Antibiotic
Class
Major Nursing Consideration
Amoxicillin/clavulanate (Augmentin)
Beta-lactam combination• Amoxicillin (penicillin)• + Clavulanate (beta-lactamase inhibitor)
GI upset common (diarrhea, nausea)• Take with food to reduce GI side effects• Broader spectrum than amoxicillin alone (covers beta-lactamase-producing bacteria)• Assess penicillin allergy (cross-reactivity risk)
Cephalexin (Keflex)
Cephalosporin (1st generation)
Assess penicillin allergy:• 5-10% cross-reactivity with penicillins• If severe penicillin allergy (anaphylaxis), avoid• If mild allergy (rash only), usually safe• GI upset: Take with food• Good for: Skin infections, UTIs, strep throat
Vancomycin (Vancocin)
Glycopeptide
Infuse slowly (over 1-2 hours):• Red Man Syndrome if too fast (flushing, rash, hypotension, itching)• NOT true allergy, but histamine release• Monitor trough levels(draw 30 min before next dose)• Nephrotoxic:Check Cr, BUN• Ototoxic: Assess hearing (rare)
Gentamicin
Aminoglycoside
NEPHROTOXIC & OTOTOXIC:• Monitor kidney function closely (Cr, BUN, urine output)• Monitor drug levels: Peak and trough- Trough <2 mcg/mL (nephrotoxicity if high)•Assess hearing: Tinnitus, hearing loss (can be irreversible)• IV administration: Over 30-60 minutes• Increased risk with vancomycin, loop diuretics, NSAIDs
Metronidazole (Flagyl)
Nitroimidazole• Antiparasitic• Antibacterial (anaerobes)
DISULFIRAM REACTION with alcohol:•Severe nausea, vomiting, flushing, headache, chest pain• AVOID alcohol during treatment + 48 hours after• Used for: C. difficile, Giardia, anaerobic infections, BV• Metallic tastecommon• Dark urine (harmless)
Rifampin (Rifadin)
Antimycobacterial• First-line TB drug
Turns bodily fluids orange-red:• Urine, tears, sweat, saliva (WARN PATIENT—harmless but stains contact lenses)• Hepatotoxic: Monitor LFTs• Multiple drug interactions (potent CYP450 inducer): - Reduces effectiveness of: Birth control pills, warfarin, many others•Always part of multi-drug regimen (never monotherapy—resistance develops rapidly)
ADDITIONAL TEACHING:
Penicillin Allergy: - Most common antibiotic allergyreported (~10% claim allergy) - BUT: Only 1-2% have true allergy (many “allergies” are GI upset, childhood rash misattributed) - Cross-reactivity: - Cephalosporins: 5-10% (avoid if severe reaction) - Carbapenems: 1% (generally safe even with penicillin allergy) - Severe reactions:Anaphylaxis, Stevens-Johnson syndrome (rare but serious)
Antibiotic Stewardship Points: - Complete full course(even if feeling better) - Take at evenly spaced intervals(maintains blood levels) - Report adverse effects (don’t just stop taking) - Don’t share or save antibiotics for later -Don’t demand antibiotics for viral infections
TRANSFUSION REACTION COMPARISON: Compare these FOUR types of transfusion reactions: 1.Febrile non-hemolytic (most common) 2.Allergic/Urticarial 3. Anaphylactic 4. Transfusion-Related Acute Lung Injury (TRALI)
For EACH, include: timing, symptoms, cause, and management.
Reaction Type
Timing
Symptoms
Cause
Management
Febrile Non-Hemolytic (FNHTR)
During or within 6 hours
• Fever (>1°C or 2°F rise)•Chills, rigors• Headache• FlushingNO hemolysis signs
Recipient antibodiesagainst donor WBC antigens or cytokines in stored blood
• Stop transfusion• Rule out hemolytic reaction (check vitals, hemolysis signs)•Antipyretics:Acetaminophen•May resumetransfusion if just fever/chills (per provider)•Prevention:Leukocyte-reduced (leukopoor) blood for future
Allergic/Urticarial
During transfusion(any time)
• Hives, itching(urticaria)• Skin rash, flushingNO respiratory/hemodynamic symptoms
Recipient antibodiesto donor plasma proteins
• Stop transfusion temporarily•Antihistamine:Diphenhydramine (Benadryl) 25-50 mg IV/PO• May resume once symptoms resolve (per provider)•Prevention:Antihistamine premedication for future transfusions
Anaphylactic
Within minutes of starting (first few mL)
• Severe respiratory distress(wheezing, bronchospasm, stridor)•Hypotension, shock•Angioedema(face, tongue swelling)• Hives• Abdominal cramping•Life-threatening
Severe allergy to plasma proteinsIgA deficiency(patient has anti-IgA antibodies)
• STOP IMMEDIATELY• Call rapid response•Epinephrine 0.3-0.5 mg IM (first-line)• Airway management(may need intubation)• IV fluids(hypotension)•Antihistamines, steroids (adjunct)•Future: Use washed RBCs or from IgA-deficient donor
TRALI (Transfusion-Related Acute Lung Injury)
Within 6 hours(usually 1-2 hours)
• Acute respiratory distress•Hypoxemia(severe)•Bilateral pulmonary infiltrates(CXR—“white out”)• Hypotension or hypertension• FeverLooks like ARDS
Donor antibodiesattack recipient’s neutrophils in lungs → inflammatory response → capillary leak → pulmonary edema
• STOP transfusion•Oxygen/respiratory support (may need mechanical ventilation)•Diuretics NOT helpful (not fluid overload—it’s capillary leak)•Supportive care• Usually resolves in 48-96 hours•Report to blood bank (track donor—may need to exclude)
ADDITIONAL TRANSFUSION REACTIONS:
TACO (Transfusion-Associated Circulatory Overload): -Cause: Volume overload (too much, too fast) - Symptoms:Dyspnea, crackles, JVD, hypertension, hypoxemia -Management: STOP transfusion, diuretics (Lasix), oxygen, upright position - Prevention: Slow rate (1-2 mL/kg/hr), especially in elderly, HF patients
Delayed Hemolytic Reaction: - Timing: 3-14 days post-transfusion - Cause: Anamnestic response (antibodies from prior transfusion reappear) - Symptoms: Mild—fever, anemia, jaundice - Management: Supportive
Iron Overload: - Cause: Multiple transfusions over time (each unit = 200-250 mg iron) - Risk: Chronic transfusion patients (thalassemia, sickle cell) - Management: Iron chelation therapy (deferasirox)
COMPREHENSIVE ANEMIA SCENARIO: Your 58-year-old patient presents with: - Labs: Hgb 7.2 g/dL (normal 12-16 women), Hct 22%, MCV 68 fL (low), ferritin 8 ng/mL (very low) - Symptoms: Severe fatigue, dyspnea on exertion, pale conjunctiva, spoon-shaped nails (koilonychia) - History: Heavy menstrual periods for 2 years, vegetarian diet - Vital signs: BP 98/62, HR 108, RR 22, O2 sat 94% on room air.
Answer:
1. What type of anemia does this patient have? Explain your reasoning using lab values.
2. Connect the concepts: How does anemia affect PERFUSION and OXYGENATION?
3. Why is the patient tachycardic and tachypneic? (Explain compensatory mechanisms)
4. What are FIVE priority nursing interventions?
5. What medication would you anticipate and what patient education is critical?
6. This patient needs a blood transfusion. Calculate: If Hgb is 7.2 and goal is 10, approximately how many units of packed RBCs are needed? (1 unit raises Hgb ~1 g/dL)
Iron deficiency anemia: Hgb 7.2, Hct 22%, MCV 68, ferritin 8, koilonychia, heavy menses, vegetarian diet.
Anemia lowers oxygen-carrying capacity, reducing tissue oxygen delivery even if blood flow is present.
Tachycardia and tachypnea are compensatory mechanisms to increase cardiac output and oxygen loading.
Priority nursing care: oxygen as needed, activity restriction/fall precautions, assess bleeding source, prepare for transfusion, and give iron/diet education.
Medication: ferrous sulfate with vitamin C; avoid calcium/antacids/tea/coffee near dose; expect dark stools/constipation.
Transfusion calculation: goal 10 - current 7.2 = 2.8, so about 3 units PRBCs.
COMPREHENSIVE HIV CASE: Patient: 34-year-old newly diagnosed with HIV - Labs:CD4 count 180 cells/mm³, viral load 85,000 copies/mL -Symptoms: Recurrent oral thrush, recent episode of Pneumocystis jirovecii pneumonia (PCP) - No prior antiretroviral treatment Answer: 1. Does this patient have AIDS? Explain your reasoning. 2. Why is the patient getting opportunistic infections? (Explain immune dysfunction) 3. What is the treatment plan? (Include ART, prophylaxis, monitoring) 4. What are THREE critical patient education points for starting ART? 5. What additional vaccines/prophylaxis does this patient need? 6. How will you assess treatment effectiveness?
1. AIDS DIAGNOSIS
Yes, this patient has AIDS. The CDC diagnosis requires either a CD4 count below 200 cells/mm³ or an AIDS-defining illness. This patient meets both criteria: a CD4 count of 180 cells/mm³ and a history of Pneumocystis jirovecii pneumonia (PCP). Other AIDS-defining illnesses include esophageal candidiasis, cryptococcal meningitis, CMV retinitis, toxoplasmosis, Kaposi sarcoma, Mycobacterium avium complex (MAC), recurrent bacterial pneumonia, and wasting syndrome.
2. WHY OPPORTUNISTIC INFECTIONS OCCUR
CD4 T-helper cells coordinate immune function by activating B cells, CD8 T cells, and macrophages. HIV enters CD4 cells through CCR5 or CXCR4 receptors, replicates using reverse transcriptase and integrase, and progressively destroys the cells. When the CD4 count falls below 200, the immune system cannot adequately control organisms that normally cause little harm.
Candida is normally present in the mouth but can overgrow when cell-mediated immunity declines, causing oral thrush. Esophageal candidiasis is more likely with advanced immunosuppression and is AIDS-defining. PCP occurs because patients with CD4 counts below 200 cannot effectively control Pneumocystis jirovecii. Symptoms include dry cough, dyspnea, fever, and hypoxia. TMP-SMX is used for prophylaxis.
3. TREATMENT PLAN
Begin antiretroviral therapy (ART) promptly. A preferred treatment-naïve regimen is an integrase inhibitor combination, such as bictegravir/tenofovir alafenamide/emtricitabine (Biktarvy). Another option may include dolutegravir-based therapy after appropriate testing. ART lowers viral load, supports CD4 recovery, and reduces future opportunistic infections.
Opportunistic infection prophylaxis:
• PCP: TMP-SMX DS daily or three times weekly when CD4 is below 200 or with prior PCP. Alternatives include dapsone, atovaquone, or inhaled pentamidine.
• Toxoplasmosis: TMP-SMX when CD4 is below 100 and Toxoplasma IgG is positive.
• MAC: Consider azithromycin when CD4 is below 50 and effective suppressive ART cannot be started immediately.
• Continue secondary prophylaxis after a previous infection until adequate immune recovery.
Baseline tests include CBC, CMP, renal and liver function, lipids, HIV genotype, hepatitis screening, and HLA-B*5701 if abacavir is considered. Check viral load within 2–4 weeks after ART initiation and every 3–6 months. Monitor CD4 every 3–6 months initially. Assess adherence through discussion, refill history, and barriers.
4. THREE CRITICAL EDUCATION POINTS
Adherence: Take ART every day as prescribed. Missed doses can allow viral replication and drug resistance. Use alarms, pill organizers, routines, partner support, and automatic refills. Discuss cost, stigma, and side effects openly.
Side effects: Nausea, diarrhea, headache, or fatigue may occur early, but the patient should not stop ART without contacting the provider. Report severe rash, persistent vomiting or diarrhea, jaundice, dark urine, or severe fatigue immediately.
Prognosis: HIV is a manageable chronic illness. With consistent treatment and viral suppression, patients can work, exercise, maintain relationships, and have children safely with medical guidance. Undetectable equals untransmittable (U=U) for sexual transmission when viral suppression is maintained. Condoms still reduce other STI and pregnancy risks. Offer counseling and support for depression, anxiety, or stigma.
5. VACCINES AND ADDITIONAL PREVENTION
Provide indicated non-live vaccines, including pneumococcal, annual inactivated influenza, hepatitis A and B if nonimmune, Tdap, meningococcal, HPV when eligible, and COVID-19 vaccines. Avoid live vaccines such as MMR, varicella, and intranasal influenza while CD4 is below 200. Screen for tuberculosis with an IGRA or TST and treat latent TB when indicated.
6. ASSESSING TREATMENT EFFECTIVENESS
The primary goal is an undetectable viral load, generally below 50 copies/mL, within approximately six months. A falling viral load indicates treatment response; a persistent or rising level may suggest poor adherence, resistance, interactions, or the need to change therapy.
The CD4 count should gradually increase, often by about 50–150 cells/mm³ during the first year. Clinical improvement includes resolution of thrush, improved energy and weight, no new opportunistic infections, and improved quality of life. PCP prophylaxis may be discontinued after sustained CD4 recovery above 200 with viral suppression. Treatment failure is suggested by persistent viremia, declining CD4 count, poor adherence, or new opportunistic infections. Evaluate adherence, drug interactions, and resistance before adjusting the regimen.
EMERGING INFECTIONS & GLOBAL HEALTH: COVID-19 pandemic highlighted the impact of emerging infectious diseases. Answer: 1. Define “emerging infection” and give THREE examples besides COVID-19. 2. What factors contribute to emergence of new infectious diseases? (List 4) 3. How do infections become pandemics? (Explain the progression) 4. What is “One Health” approach to infectious disease? How does it apply to antibiotic resistance? 5. As a nurse, what is your role in pandemic preparedness and response?
Emerging infections spread through travel, animal reservoirs, mutation, climate/ecologic change, and weak public health systems. Nursing priorities include early recognition, isolation, PPE, reporting, specimen collection, patient education, and protecting vulnerable patients. Antibiotic resistance is driven by overuse, incomplete courses, unnecessary broad-spectrum therapy, poor infection control, agriculture use, and global spread. Use standard/contact/droplet/airborne precautions based on route and follow facility guidance. Educate patients that antibiotics do not treat viruses and must be taken exactly as prescribed.
HIV ANTIRETROVIRAL THERAPY COMPREHENSIVE:
Patient: Newly diagnosed with HIV, never treated -Starting regimen: Biktarvy (bictegravir/tenofovir alafenamide/emtricitabine) – single-tablet regimen
Answer: 1. What THREE drug classes are represented in this combination? Explain the mechanism of each. 2. Why is combination therapy essential? (Explain resistance prevention) 3. What is the PRIMARY nursing priority when starting ART? (Think adherence) 4. What are THREE major side effects to monitor for? 5. What drug interactions must you assess for? 6. How will you evaluate treatment success? (Include timeline) 7. This patient asks: “If I take my medications every day, will I ever be able to stop?” What is your evidence-based answer?
1. THREE DRUG CLASSES IN BIKTARVY
Biktarvy contains three medications from two drug classes:
• Bictegravir: An integrase strand transfer inhibitor (INSTI) that blocks HIV integrase, preventing viral DNA from entering the host cell’s DNA.
• Tenofovir alafenamide (TAF): A nucleotide reverse transcriptase inhibitor that acts as a false DNA building block, causing chain termination. It generally has less kidney and bone toxicity than older tenofovir disoproxil fumarate.
• Emtricitabine (FTC): A nucleoside reverse transcriptase inhibitor that also causes viral DNA chain termination.
TAF and FTC form the NRTI backbone, while bictegravir blocks another stage of the HIV life cycle. This three-drug, two-class regimen produces strong viral suppression.
2. WHY COMBINATION THERAPY IS ESSENTIAL
HIV replicates rapidly, and reverse transcriptase lacks proofreading ability, causing frequent mutations. With one drug, resistant viruses may survive and become dominant. Combination therapy attacks HIV at multiple stages, making simultaneous resistance much less likely. Bictegravir also has a high genetic barrier to resistance. Effective suppression reduces viral replication, mutation, transmission, and treatment failure, but consistent adherence is essential.
3. PRIMARY NURSING PRIORITY
The main priority is adherence. Missed doses can cause viral rebound, resistance, CD4 decline, treatment failure, and increased transmission risk.
Assess barriers such as side effects, depression, substance use, stigma, unstable housing, cost, food insecurity, and difficulty maintaining a routine. Strategies include alarms, pill organizers, linking the dose to a daily habit, automatic refills, support systems, and Ryan White assistance. Use a nonjudgmental approach and explain U=U: sustained viral suppression prevents sexual transmission.
4. THREE MAJOR SIDE EFFECTS
• Gastrointestinal: Nausea, diarrhea, and abdominal discomfort may occur during the first weeks. Encourage hydration, food if helpful, and prescribed symptom relief. Do not stop ART without contacting the provider.
• Renal: TAF is safer than TDF but still requires monitoring. Check baseline and periodic creatinine, eGFR, BUN, and urinalysis, especially with kidney disease, diabetes, hypertension, older age, or nephrotoxic drugs.
• Neuropsychiatric: Headache, dizziness, insomnia, vivid dreams, anxiety, depression, or rarely suicidal thoughts may occur. Screen mental health history and monitor mood. Suicidal thoughts require immediate assessment.
Also monitor weight and bone health in high-risk patients.
5. DRUG INTERACTIONS
Perform medication reconciliation at every visit, including OTC and herbal products.
• Aluminum- or magnesium-containing antacids can reduce bictegravir absorption. Biktarvy is commonly taken at least two hours before or six hours after them. Follow specific instructions for calcium and iron products.
• Carbamazepine, phenytoin, and phenobarbital may lower bictegravir levels and should generally be avoided.
• Rifampin greatly lowers bictegravir levels and is contraindicated with Biktarvy.
• St. John’s wort reduces ART levels and should not be used.
• Bictegravir can increase metformin levels; monitor for adverse effects and adjust therapy if needed.
Consult a pharmacist before adding medications.
6. EVALUATING TREATMENT SUCCESS
The primary outcome is viral suppression. Check viral load at baseline, about 2–8 weeks after starting or changing therapy, and every 3–6 months until stable. The goal is undetectable, usually below 50 copies/mL. Failure to decline or a sustained rebound requires assessment of adherence, interactions, absorption, and resistance.
CD4 count should gradually rise, although recovery is slower and may be incomplete if treatment begins very late. Clinical success includes improved energy and weight, resolved infections, no new opportunistic infections, timely refills, and consistent medication use.
7. CAN HIV MEDICATIONS EVER BE STOPPED?
No. ART suppresses HIV but does not eliminate it. HIV remains in latent reservoirs, including long-lived memory CD4 cells and tissues such as lymph nodes, the gastrointestinal tract, and central nervous system.
If ART is stopped, viral load usually rebounds within weeks, CD4 count may fall, opportunistic infection risk returns, and transmission becomes possible again. Lifelong treatment is recommended unless the patient is in a closely monitored research study.
Teach that HIV is a manageable chronic condition. Modern once-daily therapy can support a near-normal lifespan, healthy relationships, employment, pregnancy planning, and prevention of sexual transmission when viral suppression is maintained.
COMPREHENSIVE BLOOD TRANSFUSION SCENARIO:
Patient: 72-year-old with GI bleed, admitted with Hgb 6.8 g/dL, hemodynamically stable - Orders: Transfuse 2 units packed RBCs - History: Prior transfusion 20 years ago (no reactions), Type A+ blood
Your shift: 1. What are the complete pre-transfusionassessment and preparation steps? (List 8) 2. You’re 5 minutes into the first unit. Patient reports “I feel itchy and my chest feels tight.” You see hives on arms. Vitals: BP 108/68 (baseline 122/76), HR 98 (baseline 78), RR 24, O2 sat 96%. What is your step-by-step response? (Prioritize actions) 3. After treatment, provider orders to resume transfusion with premedication. What would you anticipate? Is this safe? 4. What documentation is required for this transfusion and reaction? 5. Explain blood product storage and handling: temperatures, hang time, what to do with unused products.
1. PRE-TRANSFUSION STEPS
Verify the provider’s order, product, units, rate, premedications, consent, and completed type and crossmatch. Review previous transfusions or reactions, allergies, medications, and recent hemoglobin/hematocrit.
Obtain baseline blood pressure, heart rate, respirations, temperature, oxygen saturation, lung sounds, skin condition, and level of consciousness. Confirm a patent 18- or 20-gauge IV and use a dedicated line with 0.9% normal saline only.
Explain the procedure and instruct the patient to immediately report fever, chills, itching, rash, chest or back pain, difficulty breathing, or unusual discomfort.
Bring the blood directly from the blood bank. Two qualified staff members verify the patient’s identifiers, ABO/Rh compatibility, unit number, expiration, product type, and appearance. Both sign the transfusion record.
Prime filtered Y-type tubing with normal saline. Do not use dextrose or lactated Ringer’s. Begin slowly per facility policy, remain with the patient for the first 15 minutes, and document the start time, unit number, verification, and baseline vital signs.
2. RESPONSE TO AN ALLERGIC REACTION
Itching, hives, chest tightness, increased respirations, and changing vital signs may indicate an allergic reaction or developing anaphylaxis.
Immediately:
Stop the transfusion and clamp the tubing.
Maintain IV access with normal saline using new tubing or the saline side of the Y-set, per policy.
Call for help and assess airway, breathing, circulation, lung sounds, oxygen saturation, rash, and facial, lip, tongue, or airway swelling.
Notify the provider and blood bank promptly.
Monitor vital signs every 5–15 minutes and use continuous pulse oximetry.
Administer medications as ordered. Diphenhydramine may treat isolated itching or hives. Epinephrine is first-line for anaphylaxis with breathing difficulty, angioedema, or hypotension. Oxygen, IV fluids, bronchodilators, and corticosteroids may also be ordered.
Do not restart the same unit. Return the blood bag and tubing to the blood bank and collect ordered blood and urine specimens. Document symptoms, times, amount infused, interventions, notifications, and patient response. Continue observation for recurrence or worsening.
3. CAN THE TRANSFUSION BE RESUMED?
Resuming depends on the reaction and provider and blood-bank guidance. A mild reaction limited to itching or hives that fully resolves may permit a new unit with close monitoring and ordered premedication. Chest tightness, however, may indicate anaphylaxis, bronchospasm, or another serious reaction and requires further evaluation before additional blood is given.
If transfusion remains necessary, precautions may include a new unit, slower rate, extended bedside observation, prescribed antihistamine, and immediate access to emergency medications. Recurrent or severe allergic reactions may require washed red blood cells. Stop immediately if symptoms return.
4. DOCUMENTATION
Record:
• Consent, education, baseline assessment, IV site, lung sounds, and vital signs
• Product type, unit number, expiration, patient blood type, dual verification, and start time
• Vital signs during transfusion per policy
• Exact time and description of the reaction, including the patient’s words
• Objective findings, vital signs, and estimated volume infused
• Time the transfusion was stopped and normal saline started
• Provider and blood-bank notifications
• Medications and other interventions
• Patient response and continued monitoring
• Specimens collected and return of the unit and tubing
Complete any required transfusion-reaction or safety report separately from the medical record.
5. STORAGE AND HANDLING
Packed red blood cells are stored at 1–6°C. Frozen plasma and cryoprecipitate are stored frozen and thawed before use. Platelets are stored at 20–24°C with gentle agitation.
Most blood components must be completed within four hours after removal from controlled storage or according to facility policy. Never store blood in a regular unit refrigerator.
Return an unopened unit promptly if it has not been started and storage requirements were maintained. Blood that was partially infused, involved in a reaction, left outside controlled storage too long, or exceeded the maximum infusion time must not be reused.
Inspect blood for clots, unusual discoloration, leaks, gas bubbles, or other abnormalities. Do not transfuse a questionable product. Use only an approved blood warmer when indicated; never use a microwave, hot-water bath, or improvised warming method.